Given the very early onset of neurological signs in the NUS1 DNM carrier in the PD study (16 years), the in-depth phenotypic description of patients carrying DNM will be of interest to better characterize the clinical expression of these mutations, in addition to the replication in other WES studies. The gene discussed is NUS1; the disease is Parkinson disease.